• Home
Scientific article
English

Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease

ContributorsAgosta, Federica; Altomare, Daniele; Festari, Cristina; Orini, Stefania; Gandolfo, Federica; Boccardi, Marina; Arbizu, Javier; Bouwman, Femke; Drzezga, Alexander; Nestor, Peter; Nobili, Flavio; Walker, Zuzana; Pagani, Marco
Published inEuropean Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 9, p. 1546-1556
Publication date2018
Abstract

To evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosis of amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington's disease (HD); and detecting metabolic changes related to cognitive impairment in (iii) ALS and (iv) HD patients.

Keywords
  • Amyotrophic Lateral Sclerosis/diagnostic imaging
  • Brain
  • Fluorodeoxyglucose F18
  • Humans
  • Huntington Disease/diagnostic imaging
  • Positron-Emission Tomography
  • Radiopharmaceuticals
Affiliation entities
Research groups
Citation (ISO format)
AGOSTA, Federica et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease. In: European Journal of Nuclear Medicine and Molecular Imaging, 2018, vol. 45, n° 9, p. 1546–1556. doi: 10.1007/s00259-018-4033-0
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1619-7070
392views
0downloads

Technical informations

Creation04/01/2019 16:20:00
First validation04/01/2019 16:20:00
Update time15/03/2023 15:43:04
Status update15/03/2023 15:43:03
Last indexation02/10/2024 20:44:38
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack